| Literature DB >> 22087794 |
Constantin S Jianu1, Ove J Lange, Trond Viset, Gunnar Qvigstad, Tom C Martinsen, Reidun Fougner, Per M Kleveland, Reidar Fossmark, Øyvind Hauso, Helge L Waldum.
Abstract
We present a case of a gastric neuroendocrine carcinoma in a patient with a history of long-term proton pump inhibitor (PPI) use. A 49-year-old man using PPI for the last 15 years due to gastroesophageal reflux disease developed progressive dysphagia, dyspepsia and weight loss. Upper gastrointestinal endoscopy, endoscopic ultrasonography and abdominal CT diagnosed a malignant tumor localized to a hiatal hernia. Fasting serum chromogranin A and gastrin concentrations were elevated (32 nmol/l and 159 pmol/l, respectively). Helicobacter pylori PCR analysis of antral biopsies was negative. Biopsies from endoscopically normal oxyntic mucosa showed enterochromaffin-like (ECL) cell hyperplasia. Tumor biopsies revealed a poorly differentiated neuroendocrine carcinoma. Sevier-Munger staining, immunohistochemistry and electron microscopy indicated ECL cell as origin of the tumor cells. Concerns have previously been raised about the safety of long-term PPI use due to a possible increased risk of cancer. This case illustrates a patient with a poorly differentiated neuroendocrine carcinoma with ECL cell characteristics probably induced by hypergastrinemia secondary to long-term PPI use.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22087794 DOI: 10.3109/00365521.2011.627444
Source DB: PubMed Journal: Scand J Gastroenterol ISSN: 0036-5521 Impact factor: 2.423